Methotrexate for maintenance of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Ei Matary, Wael ^a   Vandermeer, Ben ^b   Griffiths, Anne Marie ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; STEROID; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LEUKOPENIA; MIGRAINE; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; COLITIS, ULCERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; REMISSION INDUCTION;

EID: 70049108116     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007560.pub2     Document Type: Review

References (27)

1. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110(5): 1416-1421 [PUBMED: 8613046] (Pubitemid 26134073)
2. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38(10): 1851-1856 [PUBMED: 8404406]
3. Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oralmethotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005;21(4):385-389 [PUBMED: 15709988]
4. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999;13(12):1597-1604 [PUBMED: 10594394]
5. Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ, Sandborn WJ. Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis 2000; 6(4):286-289 [PUBMED: 11149561]
6. Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16(4):693-697 [PUBMED: 11929386] (Pubitemid 34407516)
7. Gibson P, Nathan D, John I. Subcutaneous methotrexate: a safe and effective therapy in IBD. Gastroenterology 2006;130(4 Suppl 2): A525.
8. Houben MH, van Wijk HJ, Driessen WM, van Spreeuwel JP. Methotrexate as possible treatment in refractory chronic inflammatory intestinal disease [Methotrexaat als mogelijke behandeling bij refractaire chronische inflammatoire darmziekte]. Ned Tijdschr Geneeskd 1994;138(51):2552-2556 [PUBMED: 7830804]
9. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110(5):353-356 [PUBMED: 2492786]
10. Kozarek RA, Patterson OJ, Gelfand MD, Ball TJ, Botoman VA. Long-term use of methotrexate in inflammatory bowel disease. Gastroenterology 1992;102(Suppl):A648.
11. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12(11):1227-1233 [PUBMED: 11111780] (Pubitemid 30945479)
12. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008;23(6):954-958 [PUBMED: 17559377]
13. Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002;16(10):1751-1759 [PUBMED: 12269968]
14. Siveke JT, Folwaczny C. Methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2003;17(3):479-480 [PUBMED: 12562464]
15. Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16(9):921-926 [PUBMED: 15316419] (Pubitemid 39179664)
16. A controlled randomized double-blinded multicenter study comparing methotrexate to placebo in steroid-refractory ulcerative colitis. Ongoing study September 2007.
17. Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007;26(6):779-794 [PUBMED: 17767462] (Pubitemid 47346696)
18. Chande N, MacDonald JK, MacDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, Issue 4. [Art. No.: CD006618. DOI: 10.1002/14651858.CD006618.pub2] (Pubitemid 351805294)
19. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332(5):292-297 [PUBMED: 7816064]
20. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Eng J Med 2000;342(22):1627-1632 [PUBMED: 10833208]
21. Fraser AG. Methotrexate: first-line or second-line immunomodulator?. Eur J Gastroenterol Hepatol 2003;15(3):225-231 [PUBMED: 12610315]
22. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005;15(10):705-711 [PUBMED: 16141796] (Pubitemid 41345322)
23. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org., 2008.
24. Schnabel A, Gross WL. Low-dose methotrexate in rheumatic disease - efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994;23(5):310-327 [PUBMED: 8036521] (Pubitemid 24116664)
25. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003; 98(3):530-537 [PUBMED: 12650783] (Pubitemid 36348521)
26. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95(11):3150-3156 [PUBMED: 11095334]
27. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baladassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn disease. Am J Gastroenterol 2007;102(12): 2804-2812 [PUBMED: 18042110] (Pubitemid 350179322)